Fidelity Investments
NAMS icon

Fidelity Investments’s NewAmsterdam Pharma NAMS Stock Holding History

Fidelity Investments’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350M Buy
10,339,663
+1,573,852
+18% +$51.9M 0.02% 692
2026
Q1 		$281M Buy
8,765,811
+2,352,827
+37% +$76.6M 0.01% 714
2025
Q4 		$225M Buy
6,412,984
+877,691
+16% +$31.9M 0.01% 819
2025
Q3 		$157M Buy
5,535,293
+3,630,743
+191% +$87M 0.01% 955
2025
Q2 		$34.5M Buy
1,904,550
+940,726
+98% +$17.2M ﹤0.01% 1522
2025
Q1 		$19.7M Buy
963,824
+963,612
+454,534% +$21.4M ﹤0.01% 1684
2024
Q4 		$5.45K Sell
212
-330,200
-100% -$7.01M ﹤0.01% 4651
2024
Q3 		$5.48M Buy
330,412
+86,712
+36% +$1.5M ﹤0.01% 2101
2024
Q2 		$4.68M Hold
243,700
– – ﹤0.01% 2098
2024
Q1 		$5.76M Buy
+243,700
New +$4.95M ﹤0.01% 2037

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM

Fidelity Investments's NAMS Position: Q2 2026 in Review

Fidelity Investments increased its NewAmsterdam Pharma (NAMS) stake by 18% in Q2 2026, buying an estimated $51.9M and bringing the position to 10,339,663 shares worth $350M. The position accounts for 0.02% of the portfolio, ranked #692.

Fidelity Investments first reported a position in NAMS in Q1 2024 and has held it in 10 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Fidelity Investments held 10,339,663 shares of NewAmsterdam Pharma worth $350M as of Q2 2026.
  • Fidelity Investments bought 1,573,852 NewAmsterdam Pharma shares in Q2 2026, an estimated $51.9M.
  • NewAmsterdam Pharma made up 0.02% of Fidelity Investments's portfolio in Q2 2026, its #692 holding.
  • Fidelity Investments first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 10 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.